Download File - JOHN J. HADDAD, Ph.D.
Download File - JOHN J. HADDAD, Ph.D.
Download File - JOHN J. HADDAD, Ph.D.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Dendritic Cell Vaccines for Gliomas 105<br />
12. Kikuchi T, Akasaki Y, Abe T, et al. Intratumoral injection of dendritic and irradiated<br />
glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer<br />
Immunol Immunother 2002; 51:424–430.<br />
13. Zou JP, Morford LA, Chougnet C, et al. Human glioma-induced immunosuppression<br />
involves soluble factor(s) that alters monocyte cytokine profile and surface markers.<br />
J Immunol 1999; 162:4882–4892.<br />
14. Reddy PS, Sakhuja K, Ganesh S, et al. Sustained human factor VIII expression in<br />
hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol<br />
Ther 2002; 5:63–73.<br />
15. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature<br />
1998; 392:245–252.<br />
16. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully<br />
mature and stable dendritic cells from leukapheresis products for clinical application.<br />
J Immunol Methods 1999; 223:1–15.<br />
17. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma<br />
using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52–58.<br />
18. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell<br />
carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;<br />
6:332–336.<br />
19. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with<br />
peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328–332.<br />
20. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in<br />
prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36:39–44.<br />
21. Siesjo P, Visse E, Sjogren HO. Cure of established, intracerebral rat gliomas induced<br />
by therapeutic immunizations with tumor cells and purified APC or adjuvant IFNgamma<br />
treatment. J Immunother Emphasis Tumor Immunol 1996; 19:334–345.<br />
22. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in<br />
patients with metastatic melanoma to CD34(þ) progenitor-derived dendritic cell<br />
vaccine. Cancer Res 2001; 61:6451–6458.<br />
23. Brooks WH, Netsky MG, Normansell DE, et al. Depressed cell-mediated immunity<br />
in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive<br />
factor. J Exp Med 1972; 136:1631–1647.<br />
24. Young HF, Sakalas R, Kaplan AM. Inhibition of cell-mediated immunity in patients<br />
with brain tumors. Surg Neurol 1976; 5:19–23.<br />
25. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55:115–122.<br />
26. Baxevanis CN, Reclos GJ, Gritzapis AD, et al. Elevated prostaglandin E2 production<br />
by monocytes is responsible for the depressed levels of natural killer and<br />
lymphokine-activated killer cell function in patients with breast cancer. Cancer<br />
1993; 72:491–501.<br />
27. Chemnitz JM, Driesen J, Classen S, et al. Prostaglandin E2 impairs CD4þ T cell<br />
activation by inhibition of lck: implications in Hodgkin’s lymphoma. Cancer Res<br />
2006; 66:1114–1122.<br />
28. Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming<br />
growth factor-beta. <strong>Ph</strong>armacol Ther 2003; 98:257–265.<br />
29. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to<br />
spontaneous T cell differentiation and autoimmune disease. Immunity 2000;<br />
12:171–181.